Title: EPIDEMIOLOGY, TREATMENT PATTERN, AND SURVIVAL IN CANADIAN PATIENTS WITH CHRONIC HEPATITIS B RELATED HEPATOCELLULAR CARCINOMA

Background: Hepatocellular carcinoma (HCC) is the second-most frequent cause of malignancy-associated death. We described the outcomes of CHB-HCC patients in Canada.

Purpose: We aimed to describe the outcomes of Canadian CHB-HCC patients.

Method: Data was collected from January 1, 2012, to December 31, 2022, from a national cohort of subjects mono-infected with CHB and HCC.

Results: Of 6711 CHB patients who met inclusion criteria, 232 (3.5%) developed HCC. The CHB-HCC cohort had a higher proportion of male and SEA patients (p<0001). HCC patients were followed for 15 months (IQR 2-69) prior to diagnosis, and 41 months (IQR 19-87) post-diagnosis. 53% of patients were diagnosed during surveillance protocols and 81% were diagnosed as BCLC 0-A, with 84% survival in follow-up. 38% of patients received ablation, 16% TACE, 25% resection, 17% transplanted, 8% systemic therapy, and 6% received palliative therapy. Patient treatment had an 82% concordance with BCLC guidelines.

Conclusion: Majority of patients with CHB-HCC were detected with early-stage HCC and received treatment with curative intent.